MAPT and Alzheimer disease: In total AD patients, the levels of plasma TG significantly and negatively predicted CSF t‐tau level (β = −62.68, B/H adjusted p = 0.006) and CSF p‐tau 181 level (β = −9.06, B/H adjusted p = 0.001).